Light therapy for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This study is testing whether shining a special light on the eye, called photobiomodulation, can help people with dry age-related macular degeneration (AMD). If you have dry AMD and are willing to participate, you will receive the light treatment and be monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with dry age-related macular degeneration (AMD).
- You need to be able to follow the study instructions and communicate with the doctors.
- You will need to sign a consent form before participating.
- You cannot have certain types of AMD, like wet AMD or geographic atrophy that affects the center of your vision (for US sites).
- You must not have used photosensitizing agents (like certain medications) within 30 days before treatment.
- You must not be sensitive to light or have conditions like epilepsy or migraines triggered by light.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
This trial tests a special optical device that may improve vision for people with legally blind dry age-related macular degeneration (AMD). It focuses on improving how well you can see, despite the damage to the center of your retina.
This study tests a device that delivers mild electrical stimulation to the eye to see if it can improve vision in people with early or intermediate dry age-related macular degeneration. It aims to find a safe treatment that may slow down the disease or improve visual function.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This study tests a light-based therapy called photobiomodulation for dry age-related macular degeneration (AMD). It aims to see if this treatment can help preserve vision in the dry AMD eye, and includes people who have dry AMD in one eye and wet AMD in the other.
This study tests whether low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The therapy is a painless light treatment that you might receive in multiple sessions, and the study aims to see if it can slow or improve vision decline.
Hear when a new Dry Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.